Glenmark Pharmaceuticals Ltd (GLEN.NS)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|47||2011||Executive Chairman of the Board, Chief Executive Officer, Managing Director|
|2017||President, Global Chief Financial Officer|
|2017||Compliance Officer, Company Secretary|
|2017||Executive Director - Global General Counsel, Executive Director|
|2017||Director - Corporate Affairs|
- Indian shares slump as global sell-off returns
- BRIEF-India's Glenmark Pharmaceuticals Dec-Qtr Consol Profit Falls 78 Pct
- BRIEF-Glenmark Pharma Gets Permission From CDSCO For Phase IIb Dose Range Finding Study For GRC 27864
- BRIEF-Ligand Pharma And Glenmark Pharma Enter Into License Agreement
- BRIEF-Glenmark Pharmaceuticals Launches Biosimilar Of Adalimumab In India